Sirpiglenastat is under clinical development by Dracen Pharmaceuticals and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirpiglenastat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirpiglenastat overview
DRP-104 is under development for the treatment metastatic fibrolamellar hepatocellular carcinoma, pancreatic ductal adenocarcinoma (PDAC). It developed based on immuno-metabolism platform. It is administered through intravenous and subcutaneous routes. The drug candidate has active moiety of DON(6-Diazo-5-oxo-L-norleucine) which acts by as glutamine antagonist.
It was under development for treatment of hormone refractory (castration resistant, androgen-independent) prostate cancer, advanced solid tumors, and KEAP1, NFE2L2 and/or STK11 mutated metastatic non small cell lung cancer, oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer and laryngeal cancer.
Dracen Pharmaceuticals overview
Dracen Pharmaceuticals, Inc., is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients. The company is headquartered in United States.
For a complete picture of Sirpiglenastat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
